LUSHANG FREDA PHARMACEUTICAL CO.,LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 8.05 CNY | +3.07% |
|
+0.37% | -16.41% |
| Sales 2024 * | 4.79B 661M | Sales 2025 * | 5.61B 775M | Capitalization | 8.18B 1.13B |
|---|---|---|---|---|---|
| Net income 2024 * | 380M 52.46M | Net income 2025 * | 490M 67.64M | EV / Sales 2024 * | 1.71 x |
| Net cash position 2024 * | - 0 | Net cash position 2025 * | - 0 | EV / Sales 2025 * | 1.46 x |
| P/E ratio 2024 * |
21.4
x | P/E ratio 2025 * |
16.7
x | Employees | 3,651 |
| Yield 2024 * |
1.33% | Yield 2025 * |
1.7% | Free-Float | 44.11% |
More Fundamentals
* Assessed data
More news
| 1 day | +3.07% | ||
| 1 week | +0.37% | ||
| Current month | -4.62% | ||
| 1 month | -14.99% | ||
| 3 months | -1.35% | ||
| 6 months | -13.72% | ||
| Current year | -16.41% |
1 week
7.65
8.09
1 month
7.569.46
Current year
6.389.96
1 year
6.3811.75
3 years
6.2619.10
5 years
3.2619.10
10 years
2.5419.10
| Managers | Title | Age | Since |
|---|---|---|---|
Qing Wen Jia
CHM | Chairman | 53 | 19-03-05 |
Wei Yu Dai
IRC | Investor Relations Contact | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Dong Duan
BRD | Director/Board Member | 47 | 15-06-29 |
Yu Hai Su
BRD | Director/Board Member | 60 | 21-07-06 |
Rui Ping Cha
BRD | Director/Board Member | 50 | 18-07-04 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.00% | 34 M€ | +2.14% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-23 | 8.05 | +3.07% | 9,386,147 |
| 24-04-22 | 7.81 | +0.13% | 5,183,800 |
| 24-04-19 | 7.8 | -1.02% | 6,614,500 |
| 24-04-18 | 7.88 | -2.35% | 10,010,090 |
| 24-04-17 | 8.07 | +3.99% | 10,391,950 |
End-of-day quote Shanghai S.E., April 22, 2024
More quotes
Lushang Freda Pharmaceutical Co Ltd is a China-based company mainly engaged in the manufacture and sale of pharmaceuticals and cosmetics. In terms of medicine, the Company is committed to the research and development, production and sales of Chinese patent medicines, chemical medicines, and health foods. Its products cover five fields: orthopedics, gynecology, internal medicine, ophthalmology, and pediatrics. The Company's cosmetic products involve aroma therapy, aroma skin care, aroma health care, aroma health care and other fields. In terms of raw materials, derivative products, and additives, the Company is mainly engaged in the production of hyaluronic acid raw materials.
Sector
Pharmaceuticals
Calendar
2024-04-29
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
8.05
CNY
Average target price
11.75
CNY
Spread / Average Target
+45.96%
EPS Revisions
Annual profits - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -16.41% | 1.1B | |
| +27.92% | 659B | |
| +27.68% | 557B | |
| -4.59% | 359B | |
| +16.38% | 322B | |
| +9.39% | 297B | |
| +6.30% | 215B | |
| +4.80% | 210B | |
| -6.05% | 200B | |
| -8.58% | 149B |
- Stock Market
- Equities
- 600223 Stock
